Clinical Trial: Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982534) titled 'Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.' on May 13.

Brief Summary: This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis (SSc)

Intervention: BIOLOGICAL: UTAA91 injection

CAR-modified gamma delta T cells

Recruitment Status: NOT_YET_RECRUITING

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Pub...